-
公开(公告)号：US20240067746A1
公开(公告)日：2024-02-29
申请号：US18175905
申请日：2023-02-28
申请人： GlycoNex Inc.
发明人： Tong-Hsuan CHANG , Mei-Chun YANG , Liahng-Yirn LIU , Jerry TING , Shu-Yen CHANG , Yen-Ying CHEN , Yu-Yu LIN , Shu-Lun TANG
CPC分类号： C07K16/2896 , A61K47/65 , A61K47/6801 , A61K49/0058 , A61K51/1048 , C12N15/85 , C07K2317/565 , C12N2015/8518
摘要： Disclosed herein are humanized antibodies, antigen-binding fragments thereof, and antibody conjugates, that are capable of specifically binding to certain biantennary Lewis antigens, which antigens are expressed in a variety of cancers. The presently disclosed antibodies are useful to target antigen-expressing cells for treatment or detection of disease, including various cancers. Also provided are polynucleotides, vectors, and host cells for producing the disclosed antibodies and antigen-binding fragments thereof. Pharmaceutical compositions, methods of treatment and detection, and uses of the antibodies, antigen-binding fragments, antibody conjugates, and compositions are also provided.
-
公开(公告)号：US20230256122A1
公开(公告)日：2023-08-17
申请号：US18145614
申请日：2022-12-22
申请人： City of Hope
发明人： John E. Shively , Maciej Kujawski , Megan Minnix , Paul Yazaki
CPC分类号： A61K51/1048 , A61K51/1096 , A61K47/6853 , A61K47/6813 , A61P35/00
摘要： Provided herein, inter alia, are radionuclide-labeled antibodies, immunocytokines, and methods for treating cancer using combination therapy with the radionuclide-labeled antibodies and the immunocytokines.
-
公开(公告)号：US11643471B2
公开(公告)日：2023-05-09
申请号：US17815117
申请日：2022-07-26
申请人： GlycoNex Inc.
发明人： Tong-Hsuan Chang , Mei-Chun Yang , Liahng-Yirn Liu , Jerry Ting , Shu-Yen Chang , Yen-Ying Chen , Yu-Yu Lin , Shu-Lun Tang
CPC分类号： C07K16/2896 , A61K47/65 , A61K47/6801 , A61K49/0058 , A61K51/1048 , C12N15/85 , C07K2317/565 , C12N2015/8518
摘要： Disclosed herein are humanized antibodies, antigen-binding fragments thereof, and antibody conjugates, that are capable of specifically binding to certain biantennary Lewis antigens, which antigens are expressed in a variety of cancers. The presently disclosed antibodies are useful to target antigen-expressing cells for treatment or detection of disease, including various cancers. Also provided are polynucleotides, vectors, and host cells for producing the disclosed antibodies and antigen-binding fragments thereof. Pharmaceutical compositions, methods of treatment and detection, and uses of the antibodies, antigen-binding fragments, antibody conjugates, and compositions are also provided.
-
公开(公告)号：US20190233514A1
公开(公告)日：2019-08-01
申请号：US16341052
申请日：2017-10-10
发明人： Hau Wan LEUNG , Andre Boon Hwa CHOO , Mei Yee vanessa DING , Shao Weng Daniel Tan , Narayanan Gopalakrishna Iyer
CPC分类号： C07K16/2803 , A61K47/6415 , A61K47/6857 , A61K51/1048 , A61K2039/505 , A61K2039/55 , A61P35/00 , C07K16/30 , C07K16/44 , C07K2317/732 , G01N33/57473
摘要： The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.
-
公开(公告)号：US08606349B2
公开(公告)日：2013-12-10
申请号：US11980653
申请日：2007-10-31
申请人： Benny Rousso , Shlomo Ben-Haim , Michael Nagler , Omer Ziv , Ran Ravhon , Dalia Dickman , Yoel Zilberstein , Eli Dichterman , Simona Ben-Haim , Shankar Vallabhajosula , Daniel Berman , Zohar Bronshtine , Ziv Popper , Nir Weissberg , Nathaniel Roth , Haim Melman
发明人： Benny Rousso , Shlomo Ben-Haim , Michael Nagler , Omer Ziv , Ran Ravhon , Dalia Dickman , Yoel Zilberstein , Eli Dichterman , Simona Ben-Haim , Shankar Vallabhajosula , Daniel Berman , Zohar Bronshtine , Ziv Popper , Nir Weissberg , Nathaniel Roth , Haim Melman
IPC分类号： A61B6/00
CPC分类号： A61B6/44 , A61B5/06 , A61B5/415 , A61B5/416 , A61B5/418 , A61B5/7285 , A61B6/037 , A61B6/0414 , A61B6/425 , A61B6/4258 , A61B6/4266 , A61B6/4275 , A61B6/4291 , A61B6/488 , A61B6/501 , A61B6/502 , A61B6/507 , A61B6/541 , A61B6/547 , A61B6/548 , A61B6/583 , A61B8/0808 , A61B8/0825 , A61B8/12 , A61B8/4416 , A61B8/543 , A61K51/00 , A61K51/0478 , A61K51/1048 , G01R33/481 , G01T1/1615 , G01T1/1642 , G01T1/2985
摘要： A method of imaging, comprising: (a) providing an isotope at a low dosage in a body of a patient; (b) receiving radiation generated by said isotope from said body using a radiation camera; and (c) reconstructing a 3D distribution of said isotope from said received radiation, wherein the dosage is less than ⅓ of a standard dose set forth in Table 5.
摘要翻译： 一种成像方法，包括：（a）在患者体内以低剂量提供同位素; （b）使用辐射照相机从所述身体接收由所述同位素产生的辐射; 和（c）从所述接收的辐射重建所述同位素的3D分布，其中所述剂量小于表5中列出的标准剂量的1/3。
-
公开(公告)号：US20130109073A1
公开(公告)日：2013-05-02
申请号：US13604228
申请日：2012-09-05
IPC分类号： C12N9/96
CPC分类号： C12N9/96 , A61K39/395 , A61K47/65 , A61K47/6813 , A61K47/6853 , A61K51/1048 , B82Y5/00 , B82Y10/00 , B82Y30/00 , C07K16/283 , C07K16/3007 , C07K16/468 , C07K2317/31 , C07K2317/55 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C07K2319/70
摘要： The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In a most preferred embodiment the complex comprises an anti-CD20 IgG antibody conjugated to four IFN-α2b moieties, although other antibodies and cytokines have been used to form effect DNL complexes.
-
公开(公告)号：US20120308477A1
公开(公告)日：2012-12-06
申请号：US13068848
申请日：2011-05-30
CPC分类号： A61N5/1014 , A61K51/1048 , A61N2005/1021
摘要： The present invention relates to a method of treating a subject having a cancer in a body cavity characterized in that it comprises the steps of: administering in said body cavity of the subject radiolabeled binding molecules which bind to an antigen expressed by cancerous cells; washing the body cavity to remove unbound radiolabeled molecules. The present invention also relates to a body cavity perfusing system for carrying out said method.
摘要翻译： 本发明涉及一种治疗体内具有癌症的受试者的方法，其特征在于其包括以下步骤：在所述体腔内施用结合癌细胞表达的抗原的放射性标记的结合分子; 清洗体腔以去除未结合的放射性标记分子。 本发明还涉及一种用于执行所述方法的体腔灌注系统。
-
公开(公告)号：US20120076728A1
公开(公告)日：2012-03-29
申请号：US13263069
申请日：2010-04-07
申请人： Anna M. Wu , Vania E. Kenanova , Tove Olafsen
发明人： Anna M. Wu , Vania E. Kenanova , Tove Olafsen
CPC分类号： C07K14/765 , A61K38/00 , A61K47/61 , A61K47/6889 , A61K51/1048 , C07K16/42 , C07K19/00 , C07K2319/30 , C07K2319/33 , C12N15/115 , C12N2310/16
摘要： This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided.
摘要翻译： 本发明提供了包含蛋白质支架的构建体，其中所述支架包含人血清白蛋白的III区，IIIa区或IIIb区，或与III，Domain IIIa或Domain IIIb具有实质序列同一性的多肽; 和与蛋白质支架共价连接的靶向部分; 和与蛋白质支架共价连接的治疗部分和/或成像部分。 可以修饰支架以调节构建体的血清药代动力学。 除了制备构建体的方法之外，还提供了构建体的治疗，成像和诊断用途。
-
9.发明申请Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities 有权具有多重功能或结合特异性的定义组合的稳定结合公开(公告)号：US20110143417A1
公开(公告)日：2011-06-16
申请号：US12968936
申请日：2010-12-15
CPC分类号： C07K16/18 , A61K39/395 , A61K47/65 , A61K47/6853 , A61K51/088 , A61K51/1048 , B82Y5/00 , B82Y10/00 , B82Y30/00 , C07K16/283 , C07K16/3007 , C07K16/468 , C07K2317/31 , C07K2317/55 , C07K2317/569 , C07K2319/00 , C07K2319/70
摘要： The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. The disclosed methods and compositions provide a simple, easy to purify way to obtain any binary compound attached to any monomeric compound, or any trinary compound.
摘要翻译： 本发明涉及用于具有多种功能和/或结合特异性的限定组合物的稳定束缚结构的方法和组合物。 具体实施方案涉及稳定的包含第一单体的同二聚体的束缚结构，其包含连接到第一前体的二聚化和对接结构域，以及包含连接到第二前体的锚定结构域的第二单体。 第一和第二前体实际上可以是任何分子或结构，例如抗体，抗体片段，抗体类似物或模拟物，适体，结合肽，结合蛋白片段，蛋白质或其他分子的已知配体，酶，可检测标记或标签， 治疗剂，毒素，药物，细胞因子，白介素，干扰素，放射性同位素，蛋白质，肽，肽模拟物，多核苷酸，RNAi，寡糖，天然或合成聚合物质，纳米颗粒，量子点，有机或无机化合物等。 组合物提供了一种简单，易于纯化的方式来获得连接到任何单体化合物或任何三元化合物上的任何二元化合物。
-
10.发明申请Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies 有权用于双特异性抗体的新型基于肽的试剂的生产和使用公开(公告)号：US20090246131A1
公开(公告)日：2009-10-01
申请号：US12481233
申请日：2009-06-09
CPC分类号： C07K16/468 , A61K47/6863 , A61K47/6899 , A61K51/1048 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
摘要翻译： 本发明涉及一种双特异性抗体或抗体片段，该双特异性抗体或抗体片段具有至少一个对目标组织有反应性的臂和至少一种其它可靶向缀合物反应的其他臂。 可靶向缀合物包含已制备抗体的半抗原。 在优选的实施方案中，半抗原是组胺 - 琥珀酰甘氨酸（HSG）。 在更优选的实施方案中，所述至少一个臂包含HSG结合679抗体的CDR序列。 可靶向缀合物连接至一种或多种治疗和/或诊断剂。 本发明提供了用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法和包含它们的试剂盒。
-
-
-
-
-
-
-
-
-
搜索结果
172 条记录 (耗时 0.074 秒)
